VIVUS (NASDAQ:VVUS) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The firm currently has a $3.00 price objective on the biopharmaceutical company’s stock. Zacks‘s target price points …
Ticker Report · 6/24/2015
Moreover, the company is facing patent challenges for Qsymia.” VIVUS (NASDAQ:VVUS) traded up 1.99% during mid-day trading on Tuesday, hitting $2.56. 754,527 shares of the company’s stock traded hands. VIVUS has a 1-year low of $2.22 and a … · 6/23/2015
... a hold rating and one has issued a buy rating to the company’s stock. VIVUS currently has a consensus rating of “Hold” and a consensus target price of $3.92. VIVUS (NASDAQ:VVUS) opened at 2.57 on Tuesday. VIVUS has a 52-week low of $2.
Mideast Times · 6/24/2015
More from Bing News
Qsymia from Vivus (NASDAQ:VVUS) saw its share rise to 30.41% ... bode well for any hopes of seeing the levels of revenue needed to cause excitement about the stock. Typically, sales peak at the end of September …
Seeking Alpha · BySpencer Osborne · 1 day ago
Belviq sales
Last month, VVUS shares sank sharply after the company’s stock rating was downgraded by Piper Jaffray. VVUS stock closed at $4.67 per share on Tuesday.
Investor Place · ByChristopher Freeburn · 5/28/2014
Vivus Inc. (VVUS) stock is up over 18% today after the US Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for Stendra. The drug was developed to treat erectile dysfunction (ED) and the recent approval allows for … · 9/19/2014
Manhattan, NY- June 20, 2015 – (Techsonian) – Cytori Therapeutics Inc (NASDAQ:CYTX) a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy compriseing …
Techsonian · 6/20/2015
Many investors appear to be quite bearish on VIVUS, Inc. (VVUS), especially if you look at the percentage of the float that is sold short for this stock. Currently, 35.97% of the float is sold short, suggesting an extreme level of bearishness for VVUS.
Yahoo Finance · 6/3/2014
Small cap obesity drug stock VIVUS, Inc (NASDAQ: VVUS), who’s potential obesity treatment peers include Arena Pharmaceuticals, Inc (NASDAQ: ARNA), EnteroMedics Inc (NASDAQ: ETRM) and Orexigen Therapeutics, Inc (NASDAQ: OREX), has …
Smallcap Network · 1/5/2015
NEW YORK (TheStreet) -- Vivus (VVUS - Get Report) rose Wednesday after Aspen Investment Fund said it is considering acquiring the pharmaceutical company for $640 million. The fund disclosed a 9.65% stake in Vivus and announced it could propose a ...
The Street · 5/28/2014